TargetChymase(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 2.30nMAssay Description:Inhibition of human skin chymaseMore data for this Ligand-Target Pair
TargetChymase(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 11nMAssay Description:Inhibition of human skin chymaseMore data for this Ligand-Target Pair
TargetChymase(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 36nMAssay Description:Inhibition of human skin chymaseMore data for this Ligand-Target Pair
TargetCathepsin G(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 38nMAssay Description:Inhibition of human neutrophil Cat GMore data for this Ligand-Target Pair
TargetCathepsin G(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 9.50E+3nMAssay Description:Inhibition of human neutrophil Cat GMore data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:Inhibitory concentration against Matrix metalloproteinase-13 (MMP-13)More data for this Ligand-Target Pair
Affinity DataIC50: 0.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:HotSpot Assay. Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tr...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.75nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.75nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
Affinity DataIC50: 0.75nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.800nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.800nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
Affinity DataIC50: 0.800nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.850nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.850nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
Affinity DataIC50: 0.850nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.900nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
Affinity DataIC50: 0.900nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.900nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1.10nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1.10nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:Inhibitory concentration against Matrix metalloproteinase-13 (MMP-13)More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1.20nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:Inhibitory concentration against Matrix metalloproteinase-13 (MMP-13)More data for this Ligand-Target Pair
Affinity DataIC50: 1.45nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1.45nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
Affinity DataIC50: 1.45nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1.60nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair